alexa Clinical Trials Currently Being Conducted with the Use of Adult Stem Cells Transplantation to Treat Retinal Diseases | OMICS International
ISSN: 2161-0991
Journal of Transplantation Technologies & Research
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Clinical Trials Currently Being Conducted with the Use of Adult Stem Cells Transplantation to Treat Retinal Diseases

Rubens c Siqueira*

Department of Ophthalmology, University of São Paulo, Brazil

*Corresponding Author:
Rubens c Siqueira
Department of Ophthalmology
School of Medicine of Ribeirao Preto
University of São Paulo /USP
Ribeirão Preto, São Paulo, Brazil
E-mail: [email protected]

Received Date: April 29, 2014; Accepted Date: May 02, 2014; Published Date: May 05, 2014

Citation: Siqueira RC (2014) Clinical Trials Currently Being Conducted with the Use of Adult Stem Cells Transplantation to Treat Retinal Diseases . J Transplant Technol Res 4:e130. doi:10.4172/2161-0991.1000e130

Copyright: © 2014 Siqueira RC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Transplantation Technologies & Research

Editorial

Current clinical trials are underway to evaluate the potential of stem cell therapy to treat multiple retinal diseases. These trials can be divided into two categories: regenerative and trophic. The regenerative therapies utilize differentiated cells such as RPE or photoreceptors that have been isolated, expanded, and derived from pluripotent embryonic or adult stem cells. The functional cells are intended to replace the damaged native cells to restore retinal function. In the trophic approach, the stem cells remain undifferentiated and are intended to repair the injured tissue or preserve function by altering the cellular microenvironment either by releasing cytokines or cell-to-cell interactions. The ability of regenerative cell therapies to replace diseased tissues has been widely publicized, yet the capacity of trophic therapies to restore visual function also holds promise [1,2]. The mechanisms by which cell therapy may be associated with functional and structural improvements in retinal diseases are unclear, but several stem cell paracrine effects may be important. For example, it has been demonstrated that, when stimulated by pro-inflammatory agents such as tumor necrosis factor, bone marrow mesenchymal stem cells release anti-inflammatory paracrine factors, exerting modulation of local inflammation, which could improve vascular permeability [3-6]. In addition, bone marrow-derived hematopoietic stem cells injected intravitreally have been shown to exert trophic rescue effects in animal models of retinal light-damage, retinal ischemia, and diabetic retinopathy [7-9].

Clinical trials are being conducted by our research group on the safety and efficacy of intravitreal injection of autologous bone marrow-derived hematopoietic stem cells (auto-BMHSC) for the treatment of retinitis pigmentosa (RP) (ClinicalTrials.gov:NCT01068561), age-related macular degeneration (NCT01518127), and retinal vascular diseases with ischemic maculopathy (severe capillary nonperfusion, as per Early Treatment Diabetic Retinopathy Study [ETDRS] criteria) (NCT01518842) . We published data regarding the safet and efficacy of intravitreal injection of autologous bone marrow-derived hematopoietic stem cells (CD34 +) in patients with retinal dystrophy [10], and reported resolution of macular edema in a patient with retinitis pigmentosa [11] and associated with ischemia (due to diabetic retinopathy in one patient and ischemic CRVO in the other patient) (in press). We showed the results of a prospective, single blind, phase II, nonrandomized clinical trial, including 20 retinitis pimentosa patients and we observed a small improvement of macular thresholds on microperimetry, concomitant to a slight hindering of the 30-2 visual field sensitivity deterioration, one year after injection [12].

We chose this route because intravitreal route has less risk and more routinely used in clinical practice compared to subretinal route. Some questions related to the use of intravitreal route are still controversial, for example, the survival time of these cells into the vitreous, the ability to penetrate these cells in the retina, the capacity of transdifferentiation in retinal cells and also if the neurotrophic factors which are produced by these cells act on the retina.

Park et al. experimentally evaluated the behavior of stem cells derived from bone marrow when injected intravitreally with respect to survival and clinical effect. They identified that the CD34 cells were injected intravitreally, were in the retinal vasculature in the fourth month after the injection and presented clinical effect observed in the electroretinogram until the eighth month [13]. This same author also initiated a pilot study that was presented at ARVO 2014 with the use of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Macular Degenerative Disease. In this report, three eyes (three subjects) were enrolled (one with dry atrophic age-related macular degeneration (AMD); two with Stargardt’s disease). The bone marrow aspiration and intravitreal injection of cells were well-tolerated and without any adverse effects during the follow-up period. A total of 3 to 7 million CD34+ cells were isolated and injected intravitreally per eye. BCVA improved 1.5 to 4 lines in the study eye during the follow-up period. No funduscopic or angiographic changes were noted during the follow-up except for some mild progression of geographic atrophy extrafoveally in both eyes of the AMD subject. Multifocal ERG showed a trend toward stabilization in the study eye compared to the contralateral eye. Full-field ERG showed stable or enhanced amplitude in the study eye. AO-OCT imaging showed new punctuate hyperreflectivity within the retinal layers suggestive of intraretinal incorporation of the stem cells in the eye with Stargardt’s disease [14].

Stem cell transplantation for retinal disease is currently transitioning from over a decade of preclinical research to phase I/II clinical trials. The results of these trials are keenly anticipated, not just regarding efficacy but also to elucidate the levels of immunosuppression required, the difference between RPE replacement and paracrine models, and to determine which delivery method is preferable. A new avenue for the treatment is being opened, and soon we will have answers regarding the cell type and technique will be more effective and safe for each group of retinal diseases.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11528
  • [From(publication date):
    May-2011 - Dec 12, 2017]
  • Breakdown by view type
  • HTML page views : 7767
  • PDF downloads : 3761
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version